journal article·2024-03

Single-cell coating with biomimetic extracellular nanofiber matrices

Slgirim Lee, James K. Carrow, Lewis A. Fraser, Jianglong Yan, Shareni Jeyamogan, Yuvaraj Sambandam, Tristan D. Clemons, Alexandra N. Kolberg-Edelbrock, Jie He, James Mathew, Zheng Jenny Zhang, Joseph P. Leventhal, Lorenzo Gallon, Liam C. Palmer, Samuel I. Stupp

Acta Biomaterialia· Volume 177
Publisher page

Abstract

Cell therapies offer great promise in the treatment of diseases and tissue regeneration, but their clinical use has many challenges including survival, optimal performance in their intended function, or localization at sites where they are needed for effective outcomes. We report here on a method to coat a biodegradable matrix of biomimetic nanofibers on single cells that could have specific functions ranging from cell signaling to targeting and helping cells survive when used for therapies. The fibers are composed of peptide amphiphile (PA) molecules that self-assemble into supramolecular nanoscale filaments. The PA nanofibers were able to create a mesh-like coating for a wide range of cell lineages with nearly 100 % efficiency, without interrupting the natural cellular phenotype or functions. The targeting abilities of this system were assessed in vitro using human primary regulatory T (hTreg) cells coated with PAs displaying a vascular cell adhesion protein 1 (VCAM-1) targeting motif. This approach provides a biocompatible method for single-cell coating that does not negatively alter cellular phenotype, binding capacity, or immunosuppressive functionality, with potential utility across a broad spectrum of cell therapies. STATEMENT OF SIGNIFICANCE: Cell therapies hold great promise in the treatment of diseases and tissue regeneration, but their clinical use has been limited by cell survival, targeting, and function. We report here a method to coat single cells with a biodegradable matrix of biomimetic nanofibers composed of peptide amphiphile (PA) molecules. The nanofibers were able to coat cells, such as human primary regulatory T cells, with nearly 100 % efficiency, without interrupting the natural cellular phenotype or functions. The approach provides a biocompatible method for single-cell coating that does not negatively alter cellular phenotype, binding capacity, or immunosuppressive functionality, with potential utility across a broad spectrum of cell therapies.
Source: europepmc · Quality: candidate unverified · Source record ↗

Research context

OpenAlex topics: RNA Interference and Gene Delivery · Supramolecular Self-Assembly in Materials · Advanced biosensing and bioanalysis techniques

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (68)

Show source-provided references
1. Cell therapy
2. Cell therapies in the clinic10.1002/btm2.10214 ↗
3. CAR T cell immunotherapy for human cancer10.1126/science.aar6711 ↗
4. Targeted therapy in cardiovascular disease: a precision therapy era
5. Engineered T cells: the promise and challenges of cancer immunotherapy10.1038/nrc.2016.97 ↗
6. Nanoencapsulation of stem cells within polyelectrolyte multilayer shells10.1002/mabi.200700061 ↗
7. Targeting improves MSC treatment of inflammatory bowel disease10.1038/mt.2010.54 ↗
8. Cell surface engineering with polyelectrolyte multilayer thin films10.1021/ja110926s ↗
9. Enhancing cell therapies from the outside in: cell surface engineering using synthetic nanomaterials10.1016/j.nantod.2011.04.001 ↗
10. Microencapsulation of cells, including islets, within stable ultra-thin membranes of maleimide-conjugated PEG-lipid with multifunctional crosslinkers10.1016/j.biomaterials.2013.01.015 ↗
11. A cytoprotective and degradable metal-polyphenol nanoshell for single-cell encapsulation10.1002/anie.201405905 ↗
12. Deterministic encapsulation of single cells in thin tunable microgels for niche modelling and therapeutic delivery10.1038/nmat4781 ↗
13. Targeted repair of heart injury by stem cells fused with platelet nanovesicles10.1038/s41551-017-0182-x ↗
14. A decade of advances in single-cell nanocoating for mammalian cells10.1002/adhm.202100347 ↗
15. Chemical remodelling of cell surfaces in living animals10.1038/nature02791 ↗
16. The construction of cell-density controlled three-dimensional tissues by coating micrometer-sized collagen fiber matrices on single cell surfaces10.1039/C4RA09085C ↗
17. Antibody targeting of stem cells to infarcted myocardium10.1634/stemcells.2005-0602 ↗
18. The effect of encapsulation of cardiac stem cells within matrix-enriched hydrogel capsules on cell survival, post-ischemic cell retention and cardiac function10.1016/j.biomaterials.2013.09.085 ↗
19. Single-cell hydrogel encapsulation for enhanced survival of human marrow stromal cells10.1016/j.biomaterials.2009.06.035 ↗
20. Single cells in nanoshells for the functionalization of living cells10.1039/C7NR08556G ↗
21. Evaluation of graphene oxide induced cellular toxicity and transcriptome analysis in human embryonic kidney cells
22. Cytotoxicity survey of commercial graphene materials from worldwide10.1038/s41699-022-00330-8 ↗
23. Cationic polymers for coating living cells10.1007/s13233-018-6145-6 ↗
24. Regulatory T cells for tolerance10.1016/j.humimm.2017.12.013 ↗
25. Targeting acute allograft rejection by immunotherapy with ex vivo-expanded natural CD4+ CD25+ regulatory T cells10.1097/01.tp.0000250731.44913.ee ↗
26. Ex vivo-expanded natural CD4+CD25+ regulatory T cells synergize with host T-cell depletion to promote long-term survival of allografts10.1111/j.1600-6143.2007.02088.x ↗
27. Generation and characterization of alloantigen-specific regulatory T cells for clinical transplant tolerance10.1038/s41598-018-19621-6 ↗
28. Clinical transplant tolerance: coming of age10.1016/j.humimm.2018.02.013 ↗
29. A phase I clinical trial with ex vivo expanded recipient regulatory T cells in living donor kidney transplants10.1038/s41598-018-25574-7 ↗
30. Cellular and functional biomarkers of clinical transplant tolerance10.1016/j.humimm.2018.01.009 ↗
31. Nonchimeric HLA-identical renal transplant tolerance: regulatory immunophenotypic/genomic biomarkers10.1111/ajt.13416 ↗
32. Immune reconstitution/immunocompetence in recipients of kidney plus hematopoietic stem/facilitating cell transplants10.1097/TP.0000000000000605 ↗
33. Massive ex vivo expansion of human natural regulatory T cells (Tregs) with minimal loss of in vivo functional activity10.1126/scitranslmed.3001809 ↗
34. Regulatory T cells in solid organ transplantation10.1002/cti2.1099 ↗
35. Ameliorative impact of mycophenolate mofetil on diabetic kidney disease; a review on current knowledge10.15171/ipp.2018.19 ↗
36. Distribution of cell adhesion molecules (ICAM-1, VCAM-1, ELAM-1) in renal tissue during allograft rejection10.1097/00007890-199303000-00027 ↗
37. Self-assembly and mineralization of peptide-amphiphile nanofibers10.1126/science.1063187 ↗
38. Peptide supramolecular materials for therapeutics10.1039/C7CS00735C ↗
39. Instructing cells with programmable peptide DNA hybrids10.1038/ncomms15982 ↗
40. Bioactive scaffolds with enhanced supramolecular motion promote recovery from spinal cord injury10.1126/science.abh3602 ↗
41. Supramolecular interactions and morphology of self-assembling peptide amphiphile nanostructures10.1021/acs.nanolett.1c01737 ↗
42. Selective differentiation of neural progenitor cells by high-epitope density nanofibers10.1126/science.1093783 ↗
43. Supramolecular nanostructure activates TrkB receptor signaling of neuronal cells by mimicking brain-derived neurotrophic factor10.1021/acs.nanolett.8b02317 ↗
44. Sulfated glycopeptide nanostructures for multipotent protein activation10.1038/nnano.2017.109 ↗
45. Sulfated glycopeptide nanostructures for multipotent protein activation10.1038/nnano.2017.109 ↗
46. Supramolecular Self-assembling peptides to deliver bone morphogenetic proteins for skeletal regeneration10.1016/j.bone.2020.115565 ↗
47. Injectable biomimetic liquid crystalline scaffolds enhance muscle stem cell transplantation10.1073/pnas.1708142114 ↗
48. Supramolecular design of self-assembling nanofibers for cartilage regeneration10.1073/pnas.0906501107 ↗
49. Shape-dependent targeting of injured blood vessels by peptide amphiphile supramolecular nanostructures10.1002/smll.201403429 ↗
50. Self-assembled peptide amphiphile nanofibers for controlled therapeutic delivery to the atherosclerotic niche
51. Tissue-factor targeted peptide amphiphile nanofibers as an injectable therapy to control hemorrhage10.1021/acsnano.5b06025 ↗
52. Development of optimized tissue-factor-targeted peptide amphiphile nanofibers to slow noncompressible torso hemorrhage10.1021/acsnano.9b09243 ↗
53. DND-CAT's new triple area detector system for simultaneous data collection at multiple length scales10.1016/j.nima.2010.12.045 ↗
54. GSAS-II: the genesis of a modern open-source all purpose crystallography software package10.1107/S0021889813003531 ↗
55. Static adhesion assay for the study of integrin activation in T lymphocytes10.3791/51646-v ↗
56. Astragalus polysaccharides suppress ICAM-1 and VCAM-1 expression in TNF-α-treated human vascular endothelial cells by blocking NF-κB activation10.1038/aps.2013.46 ↗
57. Tuning supramolecular rigidity of peptide fibers through molecular structure10.1021/ja908560n ↗
58. A self-assembly pathway to aligned monodomain gels10.1038/nmat2778 ↗
59. In vivo migration of endogenous brain progenitor cells guided by an injectable peptide amphiphile biomaterial10.1002/term.2644 ↗
60. Biomimetic nanoparticles for inflammation targeting10.1016/j.apsb.2017.12.002 ↗
61. Noninvasive vascular cell adhesion molecule-1 imaging identifies inflammatory activation of cells in atherosclerosis10.1161/CIRCULATIONAHA.106.646380 ↗
62. Reversible self-assembly of superstructured networks10.1126/science.aat6141 ↗
63. Supramolecular exchange among assemblies of opposite charge leads to hierarchical structures10.1021/jacs.0c03529 ↗
64. Fusion protein linkers: property, design and functionality10.1016/j.addr.2012.09.039 ↗
65. Using circular dichroism spectra to estimate protein secondary structure10.1038/nprot.2006.202 ↗
66. The interaction affinity between vascular cell adhesion molecule-1 (VCAM-1) and very late antigen-4 (VLA-4) analyzed by quantitative FRET10.1371/journal.pone.0121399 ↗
67. Development of bioactive peptide amphiphiles for therapeutic cell delivery10.1016/j.actbio.2009.07.031 ↗
68. Targeting improves MSC treatment of inflammatory bowel disease10.1038/mt.2010.54 ↗